Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
48 /100
MEDIUM RISK
Score updated Oct 13, 2026

LIMN — Liminatus Pharma, Inc. Dilution Risk Tracker

Track LIMN dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track LIMN — Get alerts when the score changes →

As of October 13, 2026, Liminatus Pharma, Inc. (LIMN) has a DilutionWatch DilutionScore of 48/100, rated MEDIUM dilution risk. Liminatus Pharma, Inc. has a market capitalization of $231.70M, 67.16M shares outstanding, 15 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
40
📊 Float Risk
37
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
model est. 27%
🔄 Reverse Split model est. 55%
• 50-day avg $0.19 below $1 exchange minimum
🔔 Track LIMN — Get forecast alerts →

Market Data

Market Cap$231.70M
Shares Outstanding67.16M
Float29.07M
CashN/A
Debt$1.44M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore48/100DilutionWatch score record
Shares Outstanding67.16MVerified float table or market cache
Public Float29.07MVerified float table or market cache
Market Cap$231.70MMarket data cache
Cash RunwayNot availableDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 1.

Recent SEC source mix: XBRL 1.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 380.7% shares (2026Q1 vs prior)
15 institutional holders · 1.53M shares
#1 CITADEL ADVISORS LLC 677.5K shares
#2 Cygnus Capital Advisors, LLC 350.0K shares
#3 GEODE CAPITAL MANAGEMENT, LLC 117.8K shares
+ 12 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest44.6K
Days to Cover1.8
% of Float0.1%
FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2026-08-14
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual LIMN Dilution Snapshot

Liminatus Pharma, Inc. (LIMN) has a DilutionScore of 48/100, rated Medium dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

LIMN's DilutionScore is currently 48/100 (Medium risk), with 3 score changes tracked over 89 days. The score deteriorated from 49/100 (Medium risk).

Period Score Risk Level Duration
Sep 14 – Oct 13, 202648/100MEDIUM30 days
Aug 22 – Sep 13, 202649/100MEDIUM23 days
Aug 14 – Aug 21, 202646/100MEDIUM7 days
Jul 16 – Aug 13, 202658/100HIGH29 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

LIMN shares outstanding have decreased 0.0% from 39.33M (Mar 2026) to 39.33M (Apr 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
Apr 03, 202639.33M29.07M▲ 65.82%
Mar 11, 202639.33M17.53M▲ 24.41%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track LIMN Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment LIMN files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking LIMN — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for LIMN
LIMN FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.